Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Gupta, Aditi ^a   Cao, Wei ^b   Chellaiah, Meenakshi A ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CD44; Integrin v 3; Osteoclasts; PC3 cells; PKC; RANKL; RUNX2; Smad 5

Indexed keywords

HERMES ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SMAD5 PROTEIN; TRANSCRIPTION FACTOR RUNX2; VITRONECTIN RECEPTOR;

ARTICLE; BINDING SITE; BONE METASTASIS; CANCER CELL; CELL DIFFERENTIATION; CELL ISOLATION; CELL LYSATE; CELL NUCLEUS; CONTROLLED STUDY; CULTURE MEDIUM; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ANTIGENS, CD44; BINDING SITES; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTEGRIN ALPHAVBETA3; MALE; NEOPLASM METASTASIS; OSTEOCLASTS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; SMAD5 PROTEIN;

EID: 84865967864     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-66     Document Type: Article

References (76)

1. van der Gulden JW, Kiemeney LA, Verbeek AL, Straatman H. Mortality trend from prostate cancer in The Netherlands (1950-1989) 7. Prostate 1994, 24:33-38. 10.1002/pros.2990240108, 8290387.
2. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012, 30:195-200. 10.1007/s00345-012-0824-2, 22476558.
3. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma 1. Cancer 2000, 88:2989-2994. 10.1002/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q, 10898342.
4. Sanchez-Sweatman OH, Orr FW, Singh G. Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 1998, 18:297-305. 10.1159/000024522, 10729774.
5. Dougall WC. RANKL signaling in bone physiology and cancer. Curr Opin Support Palliat Care 2007, 1:317-322. 10.1097/SPC.0b013e3282f335be, 18685382.
6. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases12. JAMA 2004, 292:490-495. 10.1001/jama.292.4.490, 15280347.
7. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176. 10.1016/S0092-8674(00)81569-X, 9568710.
8. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001, 107:1235-1244. 10.1172/JCI11685, 209296, 11375413.
9. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 2003, 63:7883-7890.
10. Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008, 7:2160-2169. 10.1158/1535-7163.MCT-08-0046, 18606716.
11. Yonou H, Ochiai A, Ashimine S, Maeda H, Horiguchi Y, Yoshioka K, et al. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer2. Prostate 2007, 67:999-1009. 10.1002/pros.20592, 17440967.
12. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005, 146:1727-1736. 10.1210/en.2004-1211, 15637291.
13. Liao J, McCauley LK. Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 2006, 25:559-571.
14. Baniwal SK, Khalid O, Sir D, Buchanan G, Coetzee GA, Frenkel B. Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol 2009, 23:1203-1214. 10.1210/me.2008-0470, 2718746, 19389811.
15. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, et al. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res 2004, 64:4506-4513. 10.1158/0008-5472.CAN-03-3851, 15231660.
16. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003, 56:13-22. 10.1002/pros.10233, 12746842.
17. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci U S A 2005, 102:1454-1459. 10.1073/pnas.0409121102, 547873, 15665096.
18. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010, 29:811-821. 10.1038/onc.2009.389, 2820596, 19915614.
19. Selvamurugan N, Shimizu E, Lee M, Liu T, Li H, Partridge NC. Identification and characterization of Runx2 phosphorylation sites involved in matrix metalloproteinase-13 promoter activation. FEBS Lett 2009, 583:1141-1146. 10.1016/j.febslet.2009.02.040, 19264160.
20. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006, 25:589-600.
21. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, et al. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 2008, 68:7795-7802. 10.1158/0008-5472.CAN-08-1078, 2596479, 18829534.
22. Kitazawa R, Mori K, Yamaguchi A, Kondo T, Kitazawa S. Modulation of mouse RANKL gene expression by Runx2 and vitamin D3. J Cell Biochem 2008, 105:1289-1297. 10.1002/jcb.21929, 18814144.
23. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo W-H, et al. Interacton and functional cooperation of PEBP2/CBF with Smads. J Biol Chem 1999, 274:31577-31582. 10.1074/jbc.274.44.31577, 10531362.
24. Javed A, Afzal F, Bae JS, Gutierrez S, Zaidi K, Pratap J, et al. Specific residues of RUNX2 are obligatory for formation of BMP2-induced RUNX2-SMAD complex to promote osteoblast differentiation. Cells Tissues Organs 2009, 189:133-137. 10.1159/000151719, 2701265,2701265, 18728344.
25. Ito Y, Zhang YW. A RUNX2/PEBP2alphaA/CBFA1 mutation in cleidocranial dysplasia revealing the link between the gene and Smad. J Bone Miner Metab 2001, 19:188-194. 10.1007/s007740170041, 11368305.
26. Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000, 20:8783-8792. 10.1128/MCB.20.23.8783-8792.2000, 86511, 11073979.
27. Jun JH, Yoon WJ, Seo SB, Woo KM, Kim GS, Ryoo HM, et al. BMP2-activated Erk/MAP kinase stabilizes Runx2 by increasing p300 levels and histone acetyltransferase activity. J Biol Chem 2010, 285:36410-36419. 10.1074/jbc.M110.142307, 2978570, 20851880.
28. Desai B, Rogers MJ, Chellaiah MA. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 2007, 6:18. 10.1186/1476-4598-6-18, 1828067, 17343740.
29. Cooper CR, Chay CH, Pienta KJ. The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 2002, 4:191-194. 10.1038/sj.neo.7900224, 1531692, 11988838.
30. Weber GF, Ashkar S. Molecular mechanisms of tumor dissemination in primary and metastatic brain cancers. Brain Res Bull 2000, 53:421-424. 10.1016/S0361-9230(00)00379-8, 11136998.
31. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002, 16:1266-1268.
32. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004, 114:1714-1725. 535068, 15599396.
33. Naor D, Sionov RV, Zahalka M, Rochman M, Holzmann B, Ish-Shalom D. Organ-specific requirements for cell adhesion molecules during lymphoma cell dissemination. Curr Top Microbiol Immunol 1998, 231:143-166. 10.1007/978-3-642-71987-5_9, 9479865.
34. Sy MS, Guo YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991, 174:859-866. 10.1084/jem.174.4.859, 2118964, 1919439.
35. Gao AC, Lou W, Dong JT, Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997, 57:846-849.
36. Noordzij MA, Van Steenbrugge GJ, Schroder FH, Van Der Kwast TH. Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer 1999, 84:478-483. 10.1002/(SICI)1097-0215(19991022)84:5<478::AID-IJC5>3.0.CO;2-N, 10502724.
37. Tanne Y, Tanimoto K, Tanaka N, Ueki M, Lin YY, Ohkuma S, et al. Expression and activity of Runx2 mediated by hyaluronan during chondrocyte differentiation. Arch Oral Biol 2008, 53:478-487. 10.1016/j.archoralbio.2007.12.007, 18242579.
38. Hayer S, Steiner G, Gortz B, Reiter E, Tohidast-Akrad M, Amling M, et al. CD44 is a determinant of inflammatory bone loss. J Exp Med 2005, 201:903-914. 10.1084/jem.20040852, 2213110, 15781582.
39. Cao J, Singleton P, Majumdar S, Burghardt A, Bourguignon GJ, Halloran BP. Hyaluronan increases RANKL expression in mouse primary osteoblasts through CD44. A potential role in age-related bone loss. J Bone Miner Res 2003, 18(S2):S78. Ref Type: Abstract.
40. Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, et al. Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem 2007, 282:10814-10825. 10.1074/jbc.M606991200, 17293599.
41. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009, 26:433-446. 10.1007/s10585-009-9242-2, 2782741, 19221883.
42. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008, 98:756-765. 10.1038/sj.bjc.6604242, 2259168, 18268494.
43. Dhir R, Gau JT, Krill D, Bastacky S, Bahnson RR, Cooper DL, et al. CD44 Expression in Benign and Neoplastic Human Prostates. Mol Diagn 1997, 2:197-204. 10.1016/S1084-8592(97)80029-X, 10462610.
44. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005, 25:8581-8591. 10.1128/MCB.25.19.8581-8591.2005, 1265732, 16166639.
45. Grier DG, Thompson A, Kwasniewska A, McGonigle GJ, Halliday HL, Lappin TR. The pathophysiology of HOX genes and their role in cancer. J Pathol 2005, 205:154-171. 10.1002/path.1710, 15643670.
46. Roccisana JL, Kawanabe N, Kajiya H, Koide M, Roodman GD, Reddy SV. Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells. J Biol Chem 2004, 279:10500-10507.
47. Cao JJ, Singleton PA, Majumdar S, Boudignon B, Burghardt A, Kurimoto P, et al. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44. J Bone Miner Res 2005, 20:30-40. 10.1359/JBMR.041014, 15619667.
48. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, et al. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate 2011, 71:1668-1679. 10.1002/pros.21383, 3426349, 21432867.
49. Yu C, Yao Z, Dai J, Zhang H, Escara-Wilke J, Zhang X, et al. ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines. In Vivo 2011, 25:69-76.
50. Mori K, Kitazawa R, Kondo T, Maeda S, Yamaguchi A, Kitazawa S. Modulation of mouse RANKL gene expression by Runx2 and PKA pathway. J Cell Biochem 2006, 98:1629-1644. 10.1002/jcb.20891, 16598781.
51. Chang SF, Chang CA, Lee DY, Lee PL, Yeh YM, Yeh CR, et al. Tumor cell cycle arrest induced by shear stress: Roles of integrins and Smad. Proc Natl Acad Sci U S A 2008, 105:3927-3932. 10.1073/pnas.0712353105, 2268796, 18310319.
52. Robertson BW, Bonsal L, Chellaiah MA. Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol Cancer 2010, 9:260. 10.1186/1476-4598-9-260, 3098013, 20868520.
53. Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R, et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 2002, 277:2468-2476. 10.1074/jbc.M105947200, 11684680.
54. Robertson BW, Chellaiah MA. Osteopontin induces beta-catenin signaling through activation of Akt in prostate cancer cells. Exp Cell Res 2010, 316:1-11. 10.1016/j.yexcr.2009.10.012, 2787770, 19850036.
55. van der Deen M, Akech J, Wang T, FitzGerald TJ, Altieri DC, Languino LR, et al. The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells. J Cell Biochem 2010, 109:828-837. 2925394, 20082326.
56. Fowler M, Borazanci E, McGhee L, Pylant SW, Williams BJ, Glass J, et al. RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem 2006, 97:1-17. 10.1002/jcb.20664, 16237704.
57. Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X, et al. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res 2009, 15:4322-4335. 10.1158/1078-0432.CCR-08-3157, 19509141.
58. Afzal F, Pratap J, Ito K, Ito Y, Stein JL, van Wijnen AJ, et al. Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. J Cell Physiol 2005, 204:63-72. 10.1002/jcp.20258, 15573378.
59. Zaidi SK, Sullivan AJ, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites. Proc Natl Acad Sci U S A 2002, 99:8048-8053. 10.1073/pnas.112664499, 123018, 12060751.
60. Lee KS, Hong SH, Bae SC. Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene 2002, 21:7156-7163. 10.1038/sj.onc.1205937, 12370805.
61. Selvamurugan N, Kwok S, Partridge NC. Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells. J Biol Chem 2004, 279:27764-27773. 10.1074/jbc.M312870200, 15084595.
62. Leboy P, Grasso-Knight G, D'Angelo M, Volk SW, Lian JV, Drissi H, et al. Smad-Runx interactions during chondrocyte maturation. J Bone Joint Surg Am 2001, 83-A(Suppl 1):S15-S22.
63. Hjelmeland AB, Schilling SH, Guo X, Quarles D, Wang XF. Loss of Smad3-mediated negative regulation of Runx2 activity leads to an alteration in cell fate determination. Mol Cell Biol 2005, 25:9460-9468. 10.1128/MCB.25.21.9460-9468.2005, 1265845, 16227596.
64. Ohyama Y, Tanaka T, Shimizu T, Matsui H, Sato H, Koitabashi N, et al. Runx2/Smad3 complex negatively regulates TGF-beta-induced connective tissue growth factor gene expression in vascular smooth muscle cells. J Atheroscler Thromb 2012, 19:23-35. 10.5551/jat.9753, 21986102.
65. Tanikawa R, Tanikawa T, Hirashima M, Yamauchi A, Tanaka Y. Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway. Biochem Biophys Res Commun 2010, 394:317-322. 10.1016/j.bbrc.2010.02.175, 20206131.
66. Wang CY, Lee LH. Mutagenicity and antibacterial activity of hydroxamic acids. Antimicrob Agents Chemother 1977, 11:753. 10.1128/AAC.11.4.753, 352062, 856029.
67. Choo CK, Ling MT, Chan KW, Tsao SW, Zheng Z, Zhang D, et al. Immortalization of human prostate epithelial cells by HPV 16 E6/E7 open reading frames. Prostate 1999, 40:150-158. 10.1002/(SICI)1097-0045(19990801)40:3<150::AID-PROS2>3.0.CO;2-7, 10398276.
68. Chellaiah M, Kizer N, Silva M, Alvarez U, Kwiatkowski D, Hruska KA. Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J Cell Biol 2000, 148:665-678. 10.1083/jcb.148.4.665, 2169374, 10684249.
69. Gupta A, Lee BS, Khadeer MA, Tang Z, Chellaiah M, Abu-Amer Y, et al. Leupaxin is a critical adaptor protein in the adhesion zone of the osteoclast. J Bone Miner Res 2003, 18:669-685. 10.1359/jbmr.2003.18.4.669, 12674328.
70. Desai B, Ma T, Zhu J, Chellaiah MA. Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem 2009, 108:272-284. 10.1002/jcb.22248, 19582779.
71. Chellaiah M, Hruska KA. Osteopontin stimulates gelsolin associated phosphoinositide levels and PtdIns 3-hydroxyl kinase. Mol Biol Cell 1996, 7:743-753. 275927, 8744948.
72. Ma T, Sadashivaiah K, Chellaiah MA. Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts. J Biol Chem 2010, 285:29911-29924. 10.1074/jbc.M109.099697, 2943304, 20650888.
73. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
74. Schneider A, Younis RH, Gutkind JS. Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia 2008, 10:1295-1302. 2570606, 18953439.
75. Singh IS, Gupta A, Nagarsekar A, Cooper Z, Manka C, Hester L, et al. Heat shock co-activates interleukin-8 transcription. Am J Respir Cell Mol Biol 2008, 39:235-242. 10.1165/rcmb.2007-0294OC, 2542457, 18367728.
76. Feng P, Li TL, Guan ZX, Franklin RB, Costello LC. Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate 2002, 52:311-318. 10.1002/pros.10128, 12210492.